普罗布考联合美金刚治疗阿尔茨海默病的效果和安全性评价

目的：观察分析抗氧化剂普罗布考联合美金刚在治疗阿尔茨海默病中的效果和安全性。方法：选取某院2013年1月至2014年3月收治的确诊为阿尔茨海默病的患者95例，按照数字表法将纳入的患者随机分为观察组（n=48）和对照组（n=47）。对照组给予美金刚药物治疗，观察组患者给予美金刚联合普罗布考治疗。记录并分析治疗前和治疗后3个月和6个月患者简易精神状态量表（MMSE得分）、阿尔茨海默病评价量表-认知分量表（ADAS-cog得分）和日常生活能力量表（ADL得分）的变化、治疗6个月后治疗疗效和治疗过程总不良反应情况。结果：（1）观察组治疗后3个月和6个月的MMSE得分分别为（15.87±0.86）分、（18.24±1.01）分，均优于对照组（14.77±0.84）分、（16.72±0.97）分，且差异均有显著性（P<0.05）。（2）观察组治疗后3个月和6个月的ADAS-cog得分分别为（32.86±0.78）分、（29.01±0.51）分，均优于对照组（134.91±1.11）分、（31.76±0.64）分，且差异均有显著性（P<0.05）。（3）观察组治疗后3个月和6个月的ADL得分分别为（28.01±0.70）分、（25.69±0.51）分，均优于对照组（29.88±0.81）分、（27.79±0.58）分，且差异均有显著性（P<0.05）。（4）观察组治疗后6个月的总有效率为83.33%，显著高于对照组61.70%，且差异均有显著性（P<0.05）。（5）观察组治疗过程中总不良反应率为20.83%，和对照组17.01%相比，差异不具有显著性（P>0.05）。结论：抗氧化剂普罗布考联合美金刚治疗阿尔茨海默病效果优于单独运用美金刚，对MMSE得分、ADAS-cog得分和ADL得分均有提高，且不会加重不良反应，是一种较好的治疗方案。

Efficacy and safety of probucol combined with memantine against Alzheimer's disease

OBJECTIVE To observe the efficacy and safety of probucol combined with memantine against Alzheimer's disease. METHODS Ninty five patients diagnosed with Alzheimer's disease were enrolled from January 2013 to March 2014, randomized to the observation group (n=48) and control group (n=47) by digital table. Patients received memantine in control group, memantine combined with probucol in observation group. Mini-Mental State Examination (MMSE score), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog scores) and activities of daily living scale (ADL score) were recorded and analyzed in two groups before and after 3 and 6 months treatment, treatment efficacy after 6 months and adverse reactions during treatment were analyzed. RESULTS After 3 and 6 months of treatment, MMSE scores of observation group were (15.87±0.86),(18.24±1.01) points, superior to those in control group (14.77±0.84),(16.72±0.97) points (P<0.05). After 3 and 6 months of treatment, ADAS-cog scores of observation group were (32.86±0.78),(29.01±0.51) points, superior to those in control group (134.91±1.11),(31.76±0.64) points (P<0.05). After 3 and 6 months of treatment, ADL scores of observation group were (28.01±0.70),(25.69±0.51) points, superior to those in control group (29.88±0.81), (27.79±0.58) points (P<0.05). The total effective rate of observation group after six months was 83.33%, significantly higher than that of control group (61.70%) (P<0.05). The total rate of adverse reaction was 20.83% in observation group and 17.01% in control group (P>0.05). CONCLUSION Memantine combined with probucol has superior effects against Alzheimer's disease, can improve MMSE score, ADAS-cog scores and ADL scores, but will not increase the side effects.